CL2023003257A1 - Promotores de células de sostén vestibular y usos de los mismos. - Google Patents
Promotores de células de sostén vestibular y usos de los mismos.Info
- Publication number
- CL2023003257A1 CL2023003257A1 CL2023003257A CL2023003257A CL2023003257A1 CL 2023003257 A1 CL2023003257 A1 CL 2023003257A1 CL 2023003257 A CL2023003257 A CL 2023003257A CL 2023003257 A CL2023003257 A CL 2023003257A CL 2023003257 A1 CL2023003257 A1 CL 2023003257A1
- Authority
- CL
- Chile
- Prior art keywords
- transgene
- vestibular
- support cell
- cell promoters
- operably linked
- Prior art date
Links
- 230000001720 vestibular Effects 0.000 title abstract 4
- 108700019146 Transgenes Proteins 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000005032 SLC6A14 Human genes 0.000 abstract 1
- 108060007753 SLC6A14 Proteins 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184015P | 2021-05-04 | 2021-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003257A1 true CL2023003257A1 (es) | 2024-05-31 |
Family
ID=83932529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003257A CL2023003257A1 (es) | 2021-05-04 | 2023-11-02 | Promotores de células de sostén vestibular y usos de los mismos. |
| CL2024002594A CL2024002594A1 (es) | 2021-05-04 | 2024-08-29 | Vector de ácido nucleico que comprende un promotor de slc6a14; composición farmacéutica; y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002594A CL2024002594A1 (es) | 2021-05-04 | 2024-08-29 | Vector de ácido nucleico que comprende un promotor de slc6a14; composición farmacéutica; y su uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240218391A1 (https=) |
| EP (1) | EP4334460A4 (https=) |
| JP (1) | JP2024517250A (https=) |
| KR (1) | KR20240031224A (https=) |
| CN (1) | CN117616127A (https=) |
| AU (1) | AU2022271238A1 (https=) |
| BR (1) | BR112023023092A2 (https=) |
| CA (1) | CA3219057A1 (https=) |
| CL (2) | CL2023003257A1 (https=) |
| CO (1) | CO2023016746A2 (https=) |
| IL (1) | IL308143A (https=) |
| MX (1) | MX2023013058A (https=) |
| WO (1) | WO2022235805A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140024663A1 (en) * | 2012-07-17 | 2014-01-23 | Georgia Health Sciences University Research Institute, Inc. | Atb(0,+) amino acid transporter as a drug target for treatment of estrogen receptor-positive breast cancer |
| US20160298080A1 (en) * | 2013-12-03 | 2016-10-13 | The Johns Hopkins University | Method for highly efficient conversion of human stem cells to lineage-specific neurons |
| SG10201913266UA (en) * | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
-
2022
- 2022-05-04 AU AU2022271238A patent/AU2022271238A1/en active Pending
- 2022-05-04 MX MX2023013058A patent/MX2023013058A/es unknown
- 2022-05-04 EP EP22799511.5A patent/EP4334460A4/en active Pending
- 2022-05-04 KR KR1020237041741A patent/KR20240031224A/ko active Pending
- 2022-05-04 WO PCT/US2022/027679 patent/WO2022235805A1/en not_active Ceased
- 2022-05-04 US US18/289,031 patent/US20240218391A1/en active Pending
- 2022-05-04 CA CA3219057A patent/CA3219057A1/en active Pending
- 2022-05-04 IL IL308143A patent/IL308143A/en unknown
- 2022-05-04 JP JP2023568110A patent/JP2024517250A/ja active Pending
- 2022-05-04 BR BR112023023092A patent/BR112023023092A2/pt unknown
- 2022-05-04 CN CN202280036423.1A patent/CN117616127A/zh active Pending
-
2023
- 2023-11-02 CL CL2023003257A patent/CL2023003257A1/es unknown
- 2023-12-01 CO CONC2023/0016746A patent/CO2023016746A2/es unknown
-
2024
- 2024-08-29 CL CL2024002594A patent/CL2024002594A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022271238A9 (en) | 2024-01-04 |
| CN117616127A (zh) | 2024-02-27 |
| BR112023023092A2 (pt) | 2024-01-30 |
| WO2022235805A1 (en) | 2022-11-10 |
| IL308143A (en) | 2023-12-01 |
| CO2023016746A2 (es) | 2024-02-26 |
| MX2023013058A (es) | 2023-12-14 |
| CL2024002594A1 (es) | 2025-01-03 |
| EP4334460A1 (en) | 2024-03-13 |
| AU2022271238A1 (en) | 2023-12-14 |
| KR20240031224A (ko) | 2024-03-07 |
| EP4334460A4 (en) | 2025-11-05 |
| US20240218391A1 (en) | 2024-07-04 |
| JP2024517250A (ja) | 2024-04-19 |
| CA3219057A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016005574A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| MX2021001837A (es) | Constructos del receptor de celulas t y usos de los mismos. | |
| CL2023000294A1 (es) | Expresión selectiva de un transgene de tejidos | |
| CO2019011995A2 (es) | Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia | |
| CO2017004728A2 (es) | Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa) | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| MX2020004140A (es) | Composiciones y metodos para la eliminacion de celulas cd117+. | |
| MX2018005229A (es) | Anticuerpo anti-cd20 de tipo ii y usos del mismo. | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| CO2023016804A2 (es) | Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina | |
| CL2020002650A1 (es) | Enzimas quinureninasa humanas y sus usos | |
| CO2018002534A2 (es) | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos | |
| MX2024004443A (es) | Promotores de estereocilina y usos de estos. | |
| MX2024004652A (es) | Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas. | |
| AR104598A1 (es) | Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t | |
| ES2525009T3 (es) | Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas | |
| MX2021006504A (es) | Terapia combinada de moleculas de reclutamiento de anticuerpos (arms) y celulas asesinas naturales. | |
| CL2023003257A1 (es) | Promotores de células de sostén vestibular y usos de los mismos. | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| AR120388A1 (es) | Promotores de células de apoyo vestibulares y sus usos | |
| CL2024002306A1 (es) | Elementos reguladores de gjb2 y usos de los mismos. | |
| CO2021015405A2 (es) | Expresión de proteínas de unión a antígenos en el sistema nervioso | |
| CL2018001782A1 (es) | Metodos y composiciones para el tratamiento del sindrome de hunter. |